Navigation Links
ThermoGenesis Corp. to Announce Third Quarter Fiscal 2011 Results On May 5, 2011
Date:4/29/2011

RANCHO CORDOVA, Calif., April 29, 2011 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal third quarter ended March 31, 2011, on Thursday, May 5, 2011.

Company's Conference Call and Webcast

Management will host a conference call Thursday, May 5, 2011 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal third quarter financial results.  

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Mr. J. Melville Engle, Chairman and Chief Executive Officer and Mr. Matthew Plavan, Chief Financial Officer and Executive Vice President, Business Development will host the call to discuss the third quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.  

To listen to the audio webcast of the call during or after the event, please visit: http://www.thermogenesis.com/investors-webcasts-and-calls.aspx.

Replay

A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury.

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2011, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter
2. Major China Regenerative Medicine Company Adopts ThermoGenesis Cord Blood Stem Cell Processing And Storage Technologies
3. ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China
4. ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2011 Results on February 10, 2011
6. ThermoGenesis Corp. and TotipotentSC Receive Approval for Phase Ib Clinical Trial of Res-Q™ 60 BMC for Treatment of Critical Limb Ischemia
7. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
8. ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China
9. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
10. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
11. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Zymo Research Corp., also known as ,The Epigenetics Company, announced ... in a precise manner using the myDNAge ™ test. Based on ... of human genetics and biostatistics at the David Geffen School of ... Zymo Research,s proprietary DNAge ™ technology is used to analyze DNA ... ...
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th ... weight loss surgery patients who had received a body contouring procedure reported experiencing a ... clinic Beverly Hills Physicians (BHP), which provides both types of procedures, notes that this ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Fidget”: a fun-filled, action-packed ... retired public high school music and drama teacher who was a summa cum laude ... including a “Teacher of the Year” award. After her retirement from public school, Lynn ...
(Date:7/18/2017)... Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking place ... will be speaking on the therapeutic benefits of medical cannabis for both pediatric and ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov ... Decisions Do You Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — ... Part 11, “Final Rule for Clinical Trials Registration and Results Information,” is a ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... on a lien basis, partners with the best medical professionals who offer the ... and pre-approves each medical professional in their network, ensuring that each patient receives ...
Breaking Medicine News(10 mins):